You are here: Industry Insights > Sun Pharma

News List

Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA for Middle East & North Africa regions expresspharma
June 16, 2020
ILUMYA (tildrakizumab) is an US FDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Sun Pharma presents clinical insights of ODOMZO and LEVULAN KERASTICK + BLU-U Data for skin cancer treatment expresspharma
June 15, 2020
Analyses of long-term data confirm that the continued and clinically meaningful results of ODOMZO (sonidegib) in people with locally advanced basal cell carcinoma (laBCC) are not impacted by concomitant medicines.
Sun Pharma initiates Phase II clinical trial on AQCH as potential treatment for COVID-19 expresspharma
June 08, 2020
AQCH is the first phytopharmaceutical drug approved for clinical trial by DCGI for COVID-19 and has shown anti-SARS-CoV-2 effects in in-vitro studies.
Sun Pharma reports 59 per cent fall in consolidated profit expresspharma
May 29, 2020
The slump in profits was largely attributed to the Rs 260 crore settlement charges paid by the company to the Department of Justice in the USA and increasing expenses.
SPARC and Sun Pharma enter into license agreement for SCD-044 expresspharma
May 29, 2020
Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries announced a worldwide licensing agreement on the development and commercialisation of SCD-044.
Sun Pharma official tests positive after visit to Baddi facility expresspharma
May 11, 2020
The state government has decided to seal the factory on Monday and quarantine all employees.
Relief for Sun Pharma as regulator's probe unearths no evidence of fraud fiercepharma
September 02, 2019
Sun Pharma might soon be able to free itself of whistleblower allegations weighing on its shares—at least from the securities watchdog’s point of view.
Sun Pharma gives commercialisation license to CMS for seven products expresspharma
August 21, 2019
Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries has granted an exclusive license to a subsidiary of China Medical System Holdings (CMS) to develop and commercialise seven generic products in Mainland China.
Embattled Sun Pharma's Dilip Shanghvi, with Rs 1 salary, ranks among lowest-paid pharma CEOs fiercepharma
August 18, 2019
The helmsman of Indian’s largest drugmaker just landed among the poorest-paid of his peers—and significantly behind his firm’s median-paid employee.
Sun Pharma to develop more generic products in China biospectrumasia
August 18, 2019
Indian pharma major Sun Pharmaceutical Industries Ltd. has announced that one of its wholly owned subsidiaries has granted an exclusive license to a subsidiary of China Medical System Holdings Ltd.

Previous page 1 2 3 4 5 6 7 8 9 Next page